FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376225400> ?p ?o ?g. }

• W4376225400 abstract "In this multi-institutional retrospective study, we examined characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS). This rare lymphoma category is defined by high-grade morphologic features, most commonly Burkitt-like, and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements (so-called double-hit). Our results show that HGBL-NOS tumors are heterogeneous: 83% had a germinal center B-cell immunophenotype, 37% a dual expressor immunophenotype (MYC and BCL2 expression), 28% (single-hit) MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage 4 disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included DA-EPOCH-R (43%), R-CHOP (33%), or other intensive chemotherapy programs (11%). We found no significant differences in the rates of complete response (CR, P=0.32), progression-free (PFS, P=0.82), or overall survival (OS, P=0.60) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% (95%CI, 46.9-62.7), and OS was 68.1% (95%CI, 59.7-75.0). In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase &gt;3x upper limit of normal, and a dual expressor immunophenotype. Age &gt;60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS (13% at 2 years). Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R versus R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS." @default.
• W4376225400 created "2023-05-13" @default.
• W4376225400 creator A5000027373 @default.
• W4376225400 creator A5000227859 @default.
• W4376225400 creator A5000537427 @default.
• W4376225400 creator A5004461149 @default.
• W4376225400 creator A5005467745 @default.
• W4376225400 creator A5005904387 @default.
• W4376225400 creator A5006305719 @default.
• W4376225400 creator A5017589040 @default.
• W4376225400 creator A5020898755 @default.
• W4376225400 creator A5028705870 @default.
• W4376225400 creator A5030989742 @default.
• W4376225400 creator A5033965805 @default.
• W4376225400 creator A5034147671 @default.
• W4376225400 creator A5036974252 @default.
• W4376225400 creator A5042054886 @default.
• W4376225400 creator A5042844727 @default.
• W4376225400 creator A5043341277 @default.
• W4376225400 creator A5043944883 @default.
• W4376225400 creator A5048721506 @default.
• W4376225400 creator A5050643493 @default.
• W4376225400 creator A5051862003 @default.
• W4376225400 creator A5052070772 @default.
• W4376225400 creator A5058210944 @default.
• W4376225400 creator A5059331125 @default.
• W4376225400 creator A5061713890 @default.
• W4376225400 creator A5064091455 @default.
• W4376225400 creator A5064643006 @default.
• W4376225400 creator A5066355572 @default.
• W4376225400 creator A5067822472 @default.
• W4376225400 creator A5068602386 @default.
• W4376225400 creator A5069873622 @default.
• W4376225400 creator A5070683930 @default.
• W4376225400 creator A5071215888 @default.
• W4376225400 creator A5073364962 @default.
• W4376225400 creator A5077116363 @default.
• W4376225400 creator A5079889215 @default.
• W4376225400 creator A5080373697 @default.
• W4376225400 creator A5085565650 @default.
• W4376225400 creator A5088459737 @default.
• W4376225400 creator A5091810775 @default.
• W4376225400 date "2023-05-12" @default.
• W4376225400 modified "2023-10-01" @default.
• W4376225400 title "High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study" @default.
• W4376225400 doi "https://doi.org/10.1182/bloodadvances.2023009731" @default.
• W4376225400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37171397" @default.
• W4376225400 hasPublicationYear "2023" @default.
• W4376225400 type Work @default.
• W4376225400 citedByCount "0" @default.
• W4376225400 crossrefType "journal-article" @default.
• W4376225400 hasAuthorship W4376225400A5000027373 @default.
• W4376225400 hasAuthorship W4376225400A5000227859 @default.
• W4376225400 hasAuthorship W4376225400A5000537427 @default.
• W4376225400 hasAuthorship W4376225400A5004461149 @default.
• W4376225400 hasAuthorship W4376225400A5005467745 @default.
• W4376225400 hasAuthorship W4376225400A5005904387 @default.
• W4376225400 hasAuthorship W4376225400A5006305719 @default.
• W4376225400 hasAuthorship W4376225400A5017589040 @default.
• W4376225400 hasAuthorship W4376225400A5020898755 @default.
• W4376225400 hasAuthorship W4376225400A5028705870 @default.
• W4376225400 hasAuthorship W4376225400A5030989742 @default.
• W4376225400 hasAuthorship W4376225400A5033965805 @default.
• W4376225400 hasAuthorship W4376225400A5034147671 @default.
• W4376225400 hasAuthorship W4376225400A5036974252 @default.
• W4376225400 hasAuthorship W4376225400A5042054886 @default.
• W4376225400 hasAuthorship W4376225400A5042844727 @default.
• W4376225400 hasAuthorship W4376225400A5043341277 @default.
• W4376225400 hasAuthorship W4376225400A5043944883 @default.
• W4376225400 hasAuthorship W4376225400A5048721506 @default.
• W4376225400 hasAuthorship W4376225400A5050643493 @default.
• W4376225400 hasAuthorship W4376225400A5051862003 @default.
• W4376225400 hasAuthorship W4376225400A5052070772 @default.
• W4376225400 hasAuthorship W4376225400A5058210944 @default.
• W4376225400 hasAuthorship W4376225400A5059331125 @default.
• W4376225400 hasAuthorship W4376225400A5061713890 @default.
• W4376225400 hasAuthorship W4376225400A5064091455 @default.
• W4376225400 hasAuthorship W4376225400A5064643006 @default.
• W4376225400 hasAuthorship W4376225400A5066355572 @default.
• W4376225400 hasAuthorship W4376225400A5067822472 @default.
• W4376225400 hasAuthorship W4376225400A5068602386 @default.
• W4376225400 hasAuthorship W4376225400A5069873622 @default.
• W4376225400 hasAuthorship W4376225400A5070683930 @default.
• W4376225400 hasAuthorship W4376225400A5071215888 @default.
• W4376225400 hasAuthorship W4376225400A5073364962 @default.
• W4376225400 hasAuthorship W4376225400A5077116363 @default.
• W4376225400 hasAuthorship W4376225400A5079889215 @default.
• W4376225400 hasAuthorship W4376225400A5080373697 @default.
• W4376225400 hasAuthorship W4376225400A5085565650 @default.
• W4376225400 hasAuthorship W4376225400A5088459737 @default.
• W4376225400 hasAuthorship W4376225400A5091810775 @default.
• W4376225400 hasBestOaLocation W43762254001 @default.
• W4376225400 hasConcept C104317684 @default.
• W4376225400 hasConcept C126322002 @default.
• W4376225400 hasConcept C143998085 @default.
• W4376225400 hasConcept C159654299 @default.
• W4376225400 hasConcept C167135981 @default.
• W4376225400 hasConcept C196166836 @default.
• W4376225400 hasConcept C203014093 @default.
• W4376225400 hasConcept C2776694085 @default.

• next